Skip to content

Study · Randomized controlled trial · n = 14 · 2014

4 results

Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.

Gudipaty L, Rosenfeld NK, Fuller CS, Gallop R, Schutta MH, Rickels MR

Diabetes care26 Jun 2014Cited by 32 (Europe PMC)

PMID24969577 (opens in a new tab)PMCIDPMC4140159 (opens in a new tab)DOI10.2337/dc14-0398 (opens in a new tab)PepBankPUB-24969577
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In early type 2 diabetes, AIRmax did not change significantly after exenatide treatment compared with baseline.

    In plain wordsIn early diabetes, maximum insulin secretory capacity did not change significantly with exenatide compared with baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAIRmax versus baseline
    Study

    n = 14

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Within each group, the primary outcome measure, AIRmax, was unchanged after 6 months of treatment with exenatide or sitagliptin compared with baseline but was increased with glimepiride (P < 0.05).
    1 context sentence
    Summary · context
    We conducted a randomized controlled trial in 40 subjects with early T2D who received the GLP-1 analog exenatide (n = 14), the dipeptidyl peptidase IV inhibitor sitagliptin (n = 12), or the sulfonylurea glimepiride (n = 14) as an active comparator insulin secretagogue for 6 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In early diabetes, AIRmax change tended to be lower with exenatide than glimepiride, without statistical significance.

    In plain wordsIn early diabetes, maximum insulin secretion tended to rise less with exenatide than glimepiride, without a significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeChange in AIRmax versus glimepiride
    Study

    n: not reported in source

    Comparator
    Glimepiride
    Analysis
    Primary
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The change in AIRpot was significantly greater with glimepiride versus exenatide treatment (P < 0.05), and a similar trend was notable for the change in AIRmax (P = 0.1).
    1 context sentence
    Summary · context
    We conducted a randomized controlled trial in 40 subjects with early T2D who received the GLP-1 analog exenatide (n = 14), the dipeptidyl peptidase IV inhibitor sitagliptin (n = 12), or the sulfonylurea glimepiride (n = 14) as an active comparator insulin secretagogue for 6 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In early type 2 diabetes, AIRpot change was smaller with exenatide than glimepiride.

    In plain wordsIn early diabetes, glucose-potentiated insulin secretion changed less with exenatide than glimepiride.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseChange in AIRpot
    Study

    n: not reported in source

    Comparator
    Glimepiride
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The change in AIRpot was significantly greater with glimepiride versus exenatide treatment (P < 0.05), and a similar trend was notable for the change in AIRmax (P = 0.1).
    1 context sentence
    Summary · context
    We conducted a randomized controlled trial in 40 subjects with early T2D who received the GLP-1 analog exenatide (n = 14), the dipeptidyl peptidase IV inhibitor sitagliptin (n = 12), or the sulfonylurea glimepiride (n = 14) as an active comparator insulin secretagogue for 6 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In early diabetes, AGRmin change tended to be lower with exenatide than glimepiride, without statistical significance.

    In plain wordsIn early diabetes, glucagon secretion tended to rise less with exenatide than glimepiride, without a significant difference.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeChange in AGRmin
    Study

    n: not reported in source

    Comparator
    Glimepiride
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    α-Cell glucagon secretion (AGRmin) was also increased with glimepiride treatment (P < 0.05), and the change in AGRmin trended higher with glimepiride than with exenatide (P = 0.06).
    1 context sentence
    Summary · context
    We conducted a randomized controlled trial in 40 subjects with early T2D who received the GLP-1 analog exenatide (n = 14), the dipeptidyl peptidase IV inhibitor sitagliptin (n = 12), or the sulfonylurea glimepiride (n = 14) as an active comparator insulin secretagogue for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.